TY - JOUR
T1 - Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections
AU - Schwartz, Stephen G.
AU - Flynn, Harry W.
N1 - Publisher Copyright:
© 2013, Springer Science + Business Media New York.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - The use of anti-vascular endothelial growth factor (VEGF) agents has led to a dramatic increase in the number of intravitreal injections. Endophthalmitis remains a rare but potentially vision-threatening complication of intravitreal injections. Recent large series have estimated this risk to be about one in 3,000 injections or less. Bevacizumab, which is generally prepared by a compounding pharmacy, is associated with additional risks of contamination. Although endophthalmitis cannot be prevented in all cases, certain risk reduction strategies have been proposed, including the use of an eyelid speculum, povidone iodine, avoidance of needle contact with the eyelid margin or eyelashes, and avoidance of routine post-injection antibiotics. Despite these precautions, some patients will develop endophthalmitis following intravitreal anti-VEGF injections, and outcomes may be poor despite prompt and appropriate therapy.
AB - The use of anti-vascular endothelial growth factor (VEGF) agents has led to a dramatic increase in the number of intravitreal injections. Endophthalmitis remains a rare but potentially vision-threatening complication of intravitreal injections. Recent large series have estimated this risk to be about one in 3,000 injections or less. Bevacizumab, which is generally prepared by a compounding pharmacy, is associated with additional risks of contamination. Although endophthalmitis cannot be prevented in all cases, certain risk reduction strategies have been proposed, including the use of an eyelid speculum, povidone iodine, avoidance of needle contact with the eyelid margin or eyelashes, and avoidance of routine post-injection antibiotics. Despite these precautions, some patients will develop endophthalmitis following intravitreal anti-VEGF injections, and outcomes may be poor despite prompt and appropriate therapy.
KW - Bevacizumab
KW - Endophthalmitis
KW - Intravitreal injection
KW - Ophthalmology
KW - Ranibizumab
KW - Vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=84906812302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906812302&partnerID=8YFLogxK
U2 - 10.1007/s40135-013-0033-1
DO - 10.1007/s40135-013-0033-1
M3 - Article
AN - SCOPUS:84906812302
VL - 2
SP - 1
EP - 5
JO - Current Ophthalmology Reports
JF - Current Ophthalmology Reports
SN - 2167-4868
IS - 1
ER -